- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00952159
CYTRAM (Cytochrome P450, Tramadol) (CYTRAM)
Validation of a New Method to Detect CYP2D6 Poor Metabolizers by Monitoring Seric Concentrations of O-demethyl-tramadol and Tramadol to Make a Ratio in Comparison With Genotyping in Post-operative Patients Treated With Intravenous Tramadol
Many methods to detect CYP2D6 poor metabolizers have been validated. Some of them are based on phenotyping (metabolism of dextromethorphan or debrisoquine) and some others on genotyping. Up to now, CYP2D6 pharmacogenetics has been restricted to the field of research, in spite of poor metabolizer profile concerns 5 to 10 % of caucasian population. Nevertheless, the polymorphism of CYP2D6 is responsible for the metabolism of many drugs, particularly of two opioids involved in pain management: codeine and tramadol, their metabolites representing the most effective part of the drug effect. So prescribing codeine or tramadol in a patient poor metabolizer for the CYP2D6 is likely to be ineffective in pain management.
O-demethyl-tramadol, the metabolite of tramadol via CYP2D6, is important to consider because its analgesic effect is 2 to 4 times more potent than tramadol.
The investigators propose to phenotype CYP2D6 in post-operative patients treated by tramadol by monitoring seric concentrations of O-demethyl tramadol and tramadol to make a ratio in comparison with genotype, and to find a threshold to determine poor metabolizers. As already described, genotyping CYP2D6 will use a rapid detection method of the alleles implicated in poor metabolizer status (CYP2D6*3, *4, *5 et *6) in a Caucasian population. Sampling will be executed at two times (H24 and H48 after surgery) and only with blood (three EDTA tubes) during the post-operative monitoring of the patients. This study is likely to include 320 post-operative patients treated with intravenous tramadol during one year in three university hospitals centers (CHU of Caen, Creteil and Rouen).
The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14033
- CAEN University Hospital
-
Caen, France, 14000
- Private Clinic Saint-Martin
-
Créteil, France
- Creteil University Hospital
-
Rouen, France, 76000
- Rouen University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age > 18 years, post-operative patient treated with intravenous tramadol
- Caucasian origin
- take of blood at H24 and H48 in the post-operative monitoring
Exclusion Criteria:
- patient having already been included in the study
- patient taking opioid drugs before surgery
- patient taking one or more drugs inhibiting the CYP2D6 before or during surgery
- pregnancy or breast feeding patients having one or more contraindications for taking tramadol in post-operative analgesia
- hepatocellular incapacity (TP < 70%)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Not Poor metabolizer
|
The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping.
The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine.
The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia.
By a single take of blood and a rapid response, this method should be liked to improve pain management.
Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
|
Poor metabolizer
|
The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping.
The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine.
The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia.
By a single take of blood and a rapid response, this method should be liked to improve pain management.
Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To phenotype CYP2D6 in post-operative patients treated by tramadol by monitoring seric concentrations of O-demethyl tramadol and tramadol to make a ratio in comparison with genotype, and to find a threshold to determine poor metabolizers.
Time Frame: H24 and H48 after surgery
|
H24 and H48 after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Blandine De la Gastine, MD, University Hospital, Caen
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-A00380-57
- 09-013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-operative Patients Treated by Tramadol
-
University of California, DavisCompleted
-
Siriraj HospitalUnknownPatient Relations, Nurse | Post-operative PatientsThailand
-
Hospital Universitario La FeRecruitingCesarean Section | Post Operative Pain | Quality of Recovery | Postoperative Recovery | Ondansetron | Tramadol | QoR-15 | ObsQor-10 | Postcesarean RecoverySpain
-
EarlySense Ltd.WithdrawnPost Operative Patient | Patients Requiring PCA | Respiratory Patients | Patients in Risk of FallUnited States
-
Beth Israel Deaconess Medical CenterWithdrawnPost-operative Recovery for Cesarean Hysterectomy PatientsUnited States
-
Bispebjerg HospitalCompletedRehabilitation Strategies for Elderly Post-Operative PatientsDenmark
-
University Hospital, GhentCompletedPatients Treated by Means of 1 or More Dental ImplantsBelgium
-
Marmara UniversityCompletedPost Operative Pain | Endodontically Treated TeethTurkey
-
Ajman UniversityUniversitat Internacional de CatalunyaActive, not recruitingPost Operative Pain | Endodontically Treated TeethUnited Arab Emirates
-
Misr International UniversityCompleted
Clinical Trials on Monitoring seric concentrations of O-demethyl-tramadol and tramadol
-
Queen Elizabeth Hospital, Hong KongCompleted
-
CrystalGenomics, Inc.Completed
-
Tokat Gaziosmanpasa UniversityCompletedPain, Postoperative | PregnancyTurkey
-
Par Pharmaceutical, Inc.AAI ClinicCompletedTo Determine Bioequivalence Under Fed Conditions
-
Menarini GroupCompletedAcute PainRomania, Poland, Hungary, Latvia, Lithuania, Russian Federation, Slovakia, Spain
-
Medical University of WarsawCompletedPain, Acute | Foot FracturePoland
-
Janssen Pharmaceutical K.K.CompletedPain | Postoperative PainJapan
-
Daewon Pharmaceutical Co., Ltd.CompletedAcute Toothache Patients Above Moderate Pain After Teeth Extraction Surgery